Management of AIDS-related lymphoma

Current Opinion in Oncology

Volumn 20, Issue 5, 2008, Pages 522-528

  Levine, Alexandra M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

AIDS lymphoma; Burkitt lymphoma; Diffuse large B cell lymphoma; HIV associated Hodgkin's lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; CD40 ANTIGEN; CD40 LIGAND; CISPLATIN; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 4; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PLATINUM; PREDNISONE; PROCARBAZINE; RITUXIMAB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; VINBLASTINE; VINCRISTINE; ZIDOVUDINE; ANTINEOPLASTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; FEBRILE NEUTROPENIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION; MULTIPLE CYCLE TREATMENT; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; LYMPHOMA, AIDS-RELATED;

EID: 59649096502     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283094ec7     Document Type: Review

References (48)

1. Kaplan LD, Straus DJ, Testa MA, et al. Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336:1641-1648.
2. Levine AM, Wernz JC, Kaplan L, et al. Low dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS related lymphoma: a prospective multiinstitutional trial. JAMA 1991; 266:84-88.
3. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339-2344.
4. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19:2171-2178.
5. Hoffmann C, Wolf E, Fatkenheuer G, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17:1521-1529.
6. Lim S-T, Karim R, Tulpule A, et al. Prognostic factors in HIV related diffuse large cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol 2005; 23:8477-8482.
7. A predictive model for aggressive non-Hodgkin's lymphoma. The International non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-994.
8. Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005; 143:265-273.
9. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15:1483-1491.
10. Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004; 22:2662-2670.
11. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653-4659.
12. Gill PS, Rarick MU, Brynes RK, et al. Azidothymidine (AZT) and bone marrow failure in AIDS. Ann Intern Med 1987; 107:502-505.
13. Sparano JA, Lee J, Kaplan L, et al. Randomized phase II trial of infusional EPOCH chemotherapy given either concurrently with or sequentially followed by ritux-imab in HIV-associated lymphoma: AIDS Malignancy Consortium Trial 034: Xth International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies; 16-17 October 2006; National Cancer Institute.
14. Levine AM, Lee J, Kaplan L, et al. Efficacy and toxicity of concurrent rituximab plus infusional EPOCH in HIV associated lymphoma: AIDS Malignancy Consortium Trial 034. Proceedings of American Society of Clinical Oncology (ASCO), 3 June 2008, Chicago, Illinois, 2008; 26:460S, Abst 8527. This study describes a randomized phase II trial of the EPOCH regimen with concomitant rituximab, versus EPOCH followed sequentially by rituximab. Of importance, there was no excess in nonlymphoma death among patients receiving concomitant chemotherapy with rituximab, indicating that this combination was not associated with an increased risk of infections or infectious death. Furthermore, concomitant rituximab with EPOCH was associated with a statistically superior response rate.
15. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV associated non-Hodgkin's lymphoma: AIDS Malignancy Consortium trial 010. Blood 2005; 106:1538-1543.
16. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med 2002; 346:235-242.
17. Sehn L, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B cell lymphoma in British Columbia [Abstract 88]. Blood 2003; 102:29a.
18. Boue F, Gabarre J, Bisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV associated non-Hodgkin's lymphoma. J Clin Oncol 2006; 24:4123-4128.
19. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005; 105:1891-1897.
20. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48:1307-1312. This study outlines the various infections that have been observed in HIV-negative patients receiving rituximab.
21. Koo S, Baden LR. Infectious complications associated with immunomodulat-ing monoclonal antibodies used in the treatment of hematologie malignancy. J Natl Compr Cane Netw 2008; 6:202-213. This study confirms and expands upon the increase in unusual infections that have been described among HIV-negative patients receiving rituximab.
22. Mournier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B cell lymphoma. Blood 2003; 101:4279-4284.
23. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B cell lymphoma. Blood 2004; 103:3684-3688.
24. Bi J, Espina BM, Tulpule A, et al. High dose cytosine arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS related non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 2001; 28:416-421.
25. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high risk HIV associated lymphomas. Blood 2004; 105:874-878.
26. Spitzer TR, Ambinder RF, Lee JY, et al. Dose reduced busulfan, cyclopho-sphamide, and autologous stem cell transplantation for human immunodeficiency virus associated lymphoma: AIDS Malignancy Consortium Study 020. Biol Blood Marrow Transplant 2008; 14:59-66. This study represents a prospective, phase II multi-institutional trial of autologous stem cell transplantation in patients with relapsed/refractory AIDS-lymphoma and reports a 50% disease-free survival at 23 weeks among 20 such patients.
27. Lim ST, Karim R, Nathwani BN, et al. AIDS related Burkitt's lymphoma versus diffuse large cell lymphoma in the prehighly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005; 23:4430-4438.
28. Spina M, Simonelli C, Talamini R, Tirelli U. Patients with HIV with Burkitt's lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era. J Clin Oncol 2005; 23:8132-8133.
29. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high dose methotrexate/ ifosfamide, etopo-side, and high dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus associated Burkitt lymphoma. Cancer 2003; 98:1196-1205.
30. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94:1492-1499.
31. Oriol A, Ribera J-M, Esteve J, et al. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B cell lymphoma or leukaemia. Results of the PETHEMA-LAL3/97 study. Haematologica 2003; 88:445-453.
32. Oriol A, Ribera J-M, Brunet S, et al. Highly active antiretroviral therapy and outcome of AIDS related Burkitt's lymphoma or leukaemia. Results of the PETHAMA-LAL 3/97 study. Haematologica 2005; 90:990-992.
33. Dunleavy K, Healey Bird BR, Pittaluga S, et al. Efficacy and toxicity of dose adjusted EPOCH-rituximab in adults with newly diagnosed Burkitt lymphoma. J Clin Oncol 2007; 25; 18S (June 20 suppl): 8035. This study represents a preliminary analysis of the dose-adjusted EPOCH regimen, with concomitant rituximab, given to 19 patients with Burkitt's lymphoma, of whom six were HIV positive. The complete remission/complete remission unconfirmed rate, overall survival and progression-free survival rates were 100% at a median follow-up interval of 29 months. With no treatment-related deaths, the regimen appears worthy of further study.
34. Blinder VS, Chadburn A, Furman RR, et al. Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS Patient Care STDS 2008; 22:175-187. This study represents a nice review of the clinical, pathologic, etiologic and molecular biologic aspects of AIDS-related Burkitt's lymphoma, as well as providing an excellent summary of published therapeutic regimens and their results. The role of HAART is discussed.
35. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS related immunosuppression in adults. JAMA 2001;285:1736-1745.
36. Biggar RG, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIVAIDS. Blood 2006; 108:3786-3791.
37. Van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells: a possible explanation for the characteristic T cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999; 154:1685-1691.
38. Ohshima K, Tutiya T, Yamaguchi T, et al. Infiltration of tTh1 and Th2 lymphocytes around Hodgkin and Reed Sternberg cells in Hodgkin disease: relation with expression of CXC and CC chemokines on H and $S cells. Int J Cancer 2002; 98:567-572.
39. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99:4283-4297.
40. Levine AM. Hodgkin lymphoma: to the HAART of the matter. Blood 2006; 108:3630.
41. Levine AM. Hodgkin's disease in the setting of human immunodeficiency virus infection. J Natl Cancer Inst Monogr 1998; 23:37-42.
42. Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:422-428. This study ascertained the outcome of 104 patients with Hodgkin's lymphoma, of whom 83 were treated with HAART, whereas 21 were not. On multivariate analysis, achievement of complete remission was independently associated with having received appropriate therapy for the stage of disease, having received HAART and having had a baseline CD4 cell count of 100/μI or more.
43. Bellas C, Santon A, Manzanal A, et al. Pathological, immunological and molecular features of Hodgkin's disease associated with HIV infection: comparison with ordinary Hodgkin's disease. Am J Surg Pathol 1996; 20:1520-1524.
44. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus associated Hodgkin's disease. Br J Haematol 2004; 125:455-462.
45. Ribera J-M, Navarro JT, Oriol A, et al. Prognostic impact of highly active antiretroviral therapy in HIV related Hodgkin's disease. AIDS 2002; 16:1973-1976.
46. Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte colony stimulating factor in HIV infected patients with newly diagnosed Hodgkin's disease: a prospective multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24:444-450.
47. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100:1984-1988.
48. Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 2003; 14:1562-1569.